Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma

Journal of Clinical Oncology

Volumn 28, Issue 13, 2010, Pages 2151-2158

  Williamson, Daniel ^a   Missiaglia, Edoardo ^a   De Reyniès, Aurélien ^a   Pierron, Gaëlle ^a   Thuille, Benedicte ^a   Palenzuela, Gilles ^a   Thway, Khin ^a   Orbach, Daniel ^a   Laé, Marick ^a   Fréneaux, Paul ^a   Pritchard Jones, Kathy ^a   Oberlin, Odile ^a   Shipley, Janet ^a   Delattre, Olivier ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PAIRED BOX TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FKHR; NCOA1 PROTEIN, HUMAN; ONCOPROTEIN; PAX3 FOXO1A FUSION PROTEIN, HUMAN; PAX3 PROTEIN, HUMAN; PAX3-FOXO1A FUSION PROTEIN, HUMAN; PAX7 PROTEIN, HUMAN; STEROID RECEPTOR COACTIVATOR 1; TRANSCRIPTION FACTOR PAX7;

ARTICLE; CHROMOSOME 8; CLINICAL FEATURE; COMPARATIVE STUDY; COPY NUMBER VARIATION; EMBRYONAL RHABDOMYOSARCOMA; EVENT FREE SURVIVAL; FUSION GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; META ANALYSIS (TOPIC); METASTASIS; MOLECULAR BIOLOGY; OVERALL SURVIVAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; CHILD; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE FREE SURVIVAL; FEMALE; FRANCE; GENE EXPRESSION REGULATION; GENETIC SCREENING; GENETICS; KAPLAN MEIER METHOD; MALE; META ANALYSIS; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PREDICTION AND FORECASTING; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; UNITED KINGDOM;

CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 8; DIAGNOSIS, DIFFERENTIAL; DISEASE-FREE SURVIVAL; FEMALE; FRANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC TESTING; GREAT BRITAIN; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; NUCLEAR RECEPTOR COACTIVATOR 1; ONCOGENE PROTEINS, FUSION; PAIRED BOX TRANSCRIPTION FACTORS; PAX7 TRANSCRIPTION FACTOR; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA, ALVEOLAR; RHABDOMYOSARCOMA, EMBRYONAL; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952299529     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.3814     Document Type: Article

References (31)

1. Meza JL, Anderson J, Pappo AS, et al: Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: The Children's Oncology Group. J Clin Oncol 24:3844-3851, 2006 (Pubitemid 46630730)
2. Raney RB, Maurer HM, Anderson JR, et al: The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma 5:9-15, 2001 (Pubitemid 32319864)
3. Meyer WH, Spunt SL: Soft tissue sarcomas of childhood. Cancer Treat Rev 30:269-280, 2004 (Pubitemid 38477272)
4. Oberlin O, Rey A, Lyden E, et al: Prognostic factors in metastatic rhabdomyosarcomas: Results of a pooled analysis from United States and European cooperative groups. J Clin Oncol 26:2384-2389, 2008
5. Raney B, Anderson J, Jenney M, et al: Late effects in 164 patients with rhabdomyosarcoma of the bladder/prostate region: A report from the international workshop. J Urol 176:2190-2194, 2006
6. Anderson J, Gordon T, McManus A, et al: Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: A reproducible predictor of outcome? Br J Cancer 85:831-835, 2001
7. Sorensen PH, Lynch JC, Qualman SJ, et al: PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: A report from the Children's Oncology Group. J Clin Oncol 20:2672-2679, 2002 (Pubitemid 34575640)
8. Newton WA Jr, Gehan EA, Webber BL, et al: Classification of rhabdomyosarcomas and related sarcomas: Pathologic aspects and proposal for a new classification - an Intergroup Rhabdomyosarcoma Study. Cancer 76:1073-1085, 1995
9. Parham DM: Pediatric small-cell tumors of soft tissue, in Montgomery E, Aaron AD (eds): Clinical Pathology of Soft-Tissue Tumors. Informa Healthcare, 2001
10. Parham DM, Barr FG: Alveolar rhabdomyosarcoma, in Fletcher CDM, Unni KK, Mertens F (eds): World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France, IARC Press, 2002, pp 150-152
11. Khan J, Simon R, Bittner M, et al: Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res 58:5009-5013, 1998 (Pubitemid 28521149)
12. Anderson J, Ramsay A, Gould S, et al: PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma. Am J Pathol 159:1089-1096, 2001 (Pubitemid 32847199)
13. Wachtel M, Dettling M, Koscielniak E, et al: Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res 64:5539-5545, 2004 (Pubitemid 39095545)
14. Davicioni E, Finckenstein FG, Shahbazian V, et al: Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 66:6936-6946, 2006 (Pubitemid 44197668)
15. Laé M, Ahn EH, Mercado GE, et al: Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas. J Pathol 212:143-151, 2007 (Pubitemid 46852092)
16. Davicioni E, Anderson MJ, Finckenstein FG, et al: Molecular classification of rhabdomyosarcoma: genotypic and phenotypic determinants of diagnosis - A report from the Children's Oncology Group. Am J Pathol 174:550-564, 2009
17. Stevens MC, Rey A, Bouvet N, et al: Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: Third study of the International Society of Paediatric Oncology - SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 23:2618-2628, 2005 (Pubitemid 46179450)
18. Defachelles AS, Rey A, Oberlin O, et al: Treatment of nonmetastatic cranial parameningeal rhabdomyosarcoma in children younger than 3 years old: Results from International Society of Pediatric Oncology studies MMT 89 and 95. J Clin Oncol 27:1310-1315, 2009
19. Bergeron C, Thiesse P, Rey A, et al: Revisiting the role of doxorubicin in the treatment of rhabdomyosarcoma: An up-front window study in newly diagnosed children with high-risk metastatic disease. Eur J Cancer 44:427-431, 2008
20. Fletcher CDM, Unni KK, Mertens F: World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France, IARC Press, 2002, pp 146-152
21. Idbaih A, Marie Y, Lucchesi C, et al: BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer 122:1778-1786, 2008 (Pubitemid 351413424)
22. La Rosa P, Viara E, Hupé P, et al: VAMP: Visualization and analysis of array-CGH, transcriptome and other molecular profiles. Bioinformatics 22:2066-2073, 2006 (Pubitemid 44390895)
23. Wu Z, Irizarry RA: Preprocessing of oligonucleotide array data. Nat Biotechnol 22:656-658, 2004
24. Mootha VK, Lindgren CM, Eriksson KF, et al: PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267-273, 2003 (Pubitemid 36792858)
25. Subramanian A, Tamayo P, Mootha VK, et al: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102:15545-15550, 2005 (Pubitemid 41528093)
26. Reich M, Liefeld T, Gould J, et al: GenePattern 2.0. Nat Genet 38:500-501, 2006
27. Brunet JP, Tamayo P, Golub TR, et al: Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A 101:4164-4169, 2004 (Pubitemid 38405900)
28. Tamayo P, Scanfeld D, Ebert BL, et al: Metagene projection for cross-platform, cross-species characterization of global transcriptional states. Proc Natl Acad Sci U S A 104:5959-5964, 2007 (Pubitemid 47175641)
29. Sumegi J, Streblow R, Frayer RW, et al: Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family. Genes Chromosomes Cancer 49:224-236, 2010
30. Janoueix-Lerosey I, Schleiermacher G, Michels E, et al: Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 27:1026-1033, 2009
31. Barr FG, Duan F, Smith LM, et al: Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: A report from the Children's Oncology Group. Genes Chromosomes Cancer 48:661-672, 2009